Brisbane, Australia, 5 November 2018 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for its Japanese patent application 2015-502020 titled “A Method and Apparatus for Processing Patient Sounds” covering the use of a cough sound based audio processing pipeline for diagnosing respiratory disease. The patent protects a key component of ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease, and has an expiry date of 28 March 2033.
This patent is the third member of the patent family to be accepted, following acceptances from the United States Patent and Trademark Office and IP Australia. Patent applications covering similar subject matter are pending in Europe, China and South Korea.
“As an aging population, shortage of doctors and rising healthcare costs put pressure on the Japanese healthcare system, the use of telehealth in Japan is growing and was recently accelerated by deregulation allowing for health insurance coverage,” said Tony Keating, CEO and Managing Director of ResApp. “The granting of our core patent by the Japanese Patent Office is an important part of our commercialisation strategy in Japan and further strengthens our global intellectual property position.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in Australia and the United States have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, asthma/reactive airway disease, pneumonia, bronchiolitis, croup, chronic obstructive pulmonary disease and obstructive sleep apnoea. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.